Stocks · News reference

Citigroup Maintains Buy on Scholar Rock Holding, Raises Price Target to $60

Aug 7, 2026, 8:35 PMBenzinga Newsdesk

Citigroup analyst Geoff Meacham maintains Scholar Rock Holding (NASDAQ:SRRK) with a Buy and raises the price target from $58 to $60.

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 21, 2026, 1:11 PMBenzinga Newsdesk
Scholar Rock Removes Catalent Indiana As Commercial Fill-Finish Facility From Its Apitegromab BLA For The Treatment Of Spinal Muscular Atrophy Under Guidance From The FDA; Now On Track To Submit Apitegromab Japanese New Drug Application By End-2026
FDA review of BLA progressing well with Scholar Rock’s alternate fill-finish facilityCompany is prepared for U.S. apitegromab launch immediately upon FDA approval, which may be granted at any time through September 30,
Read original at benzinga
SRRK
BenzingaAug 13, 2026, 3:09 PMBenzinga Newsdesk
JP Morgan Maintains Overweight on Scholar Rock Holding, Raises Price Target to $63
JP Morgan analyst Tessa Romero maintains Scholar Rock Holding (NASDAQ:SRRK) with a Overweight and raises the price target from $56 to $63.
Read original at benzinga
SRRK
BenzingaAug 10, 2026, 4:03 PMVandana Singh
Scholar Rock Overcomes Manufacturing Hurdle to Keep Lead Drug FDA Review on Schedule
Scholar Rock shifts its FDA review for SMA treatment apitegromab to a secondary facility, keeping the September 30 approval date on schedule.
Read original at benzinga
NVO SRRK
BenzingaAug 10, 2026, 2:22 PMBenzinga Newsdesk
Wedbush Reiterates Outperform on Scholar Rock Holding, Maintains $58 Price Target
Wedbush analyst David Nierengarten reiterates Scholar Rock Holding (NASDAQ:SRRK) with a Outperform and maintains $58 price target.
Read original at benzinga
SRRK